Biocryst Pharmaceuticals (BCRX) EPS (Weighted Average and Diluted) (2013 - 2026)

Biocryst Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 14 years, with the latest figure at -$2.98 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 2004718.06% year-over-year to -$2.98; the trailing twelve-month figure through Mar 2026 stood at -$1.77 (down 580.77% YoY), and the FY2025 full-year result was $1.21, up 381.4% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at -$2.98, down from $1.13 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $1.13 in Q4 2025, with the low at -$2.98 in Q1 2026.
• Historically, EPS (Weighted Average and Diluted) has averaged -$0.28 across 5 years, with a median of -$0.19 in 2023.
• Annual changes were most pronounced in 2025 — EPS (Weighted Average and Diluted) jumped 969.23% — and 2026, when it sank 2004718.06%.
• Biocryst Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.38 in 2022, then advanced by 18.42% to -$0.31 in 2023, then soared by 58.06% to -$0.13 in 2024, then soared by 969.23% to $1.13 in 2025, then slumped by 363.72% to -$2.98 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$2.98 (Q1 2026), $1.13 (Q4 2025), and $0.06 (Q3 2025), per Business Quant data.